Translating clinical trials to clinical practice: Outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials

Annals of Oncology

Volumn 24, Issue 12, 2013, Pages 2972-2977

  Templeton, A J ^a   Vera Badillo, F E ^a   Wang, L ^b   Attalla, M ^a   De Gouveia, P ^a   Leibowitz Amit, R ^a   Knox, J J ^a   Moore, M ^a   Sridhar, S S ^a   Joshua, A M ^a   Pond, G R ^c   Amir, E ^a   Tannock, I F ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

Author keywords

Clinical trial; Docetaxel; Prostate cancer; Routine practice

Indexed keywords

AFLIBERCEPT; BIOLOGICAL MARKER; CUSTIRSEN; DOCETAXEL; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; GTI 2040; HEMOGLOBIN; LACTATE DEHYDROGENASE; PREDNISONE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; HEMOGLOBIN BLOOD LEVEL; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; SURVIVAL RATE; TREATMENT DURATION;

CLINICAL TRIAL; DOCETAXEL; PROSTATE CANCER; ROUTINE PRACTICE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PREDNISONE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TAXOIDS; TREATMENT OUTCOME;

EID: 84888799257     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt397     Document Type: Article

References (19)

1. Sargent D. What constitutes reasonable evidence of efficacy and effectiveness to guide oncology treatment decisions? Oncologist 2010; 15(Suppl 1): 19-23.
2. George SL. Reducing patient eligibility criteria in cancer clinical trials. J Clin Oncol 1996; 14: 1364-1370.
3. Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-1512.
4. Sridhar SS, Canil CM, Chi KN et al. A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first-line treatment in castration-resistant prostate cancer. Cancer Chemother Pharmacol 2011; 67: 927-933.
5. Small E, Demkow T, Gerritsen WR. A phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel versus docetaxel plus prednisone in symptomatic, castration-resistant prostate cancer. Proc ASCO GU Cancer Symp 2009; http://meetinglibrary.asco.org/content/20295-64.
6. Tannock IF, Fizazi K, Ivanov S et al. Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial. Lancet Oncol 2013; 14: 760-768.
7. Chi KN, Hotte SJ, Yu EY et al. Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castrationresistant prostate cancer. J Clin Oncol 2010; 28: 4247-4254.
8. Chi K, De Bono JS, Higano C. SYNERGY: A randomized phase III study comparing first-ine docetaxel/prednisone to docetaxel/prednisone plus custirsen in metastatic castration-resistant prostate canceR (mCRPC). J Clin Oncol 2011; 29: suppl, abstr TPS180. http://meetinglibrary.asco.org/content/77749-102.
9. Berthold DR, Pond GR, Soban F et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008; 26: 242-245.
10. Berthold DR, Pond GR, Roessner M et al. Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostatespecific antigen, pain, and quality of life response and survival in the TAX-327 study. Clin Cancer Res 2008; 14: 2763-2767.
11. Scher HI, Halabi S, Tannock I et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008; 26: 1148-1159.
12. Howard DN, Chambers C, Cusano F. Efficacy versus effectiveness-docetaxel and prednisone in hormone refractory prostate cancer. J Oncol Pharm Pract 2008; 14: 45-49.
13. Goyal J, Nuhn P, Huang P et al. The effect of clinical trial participation versus nonparticipation on overall survival in men receiving first-line docetaxel-containing chemotherapy for metastatic castration-resistant prostate cancer. BJU Int 2012; 110: E575-E582.
14. Chin SN, Wang L, Moore M et al. A review of the patterns of docetaxel use for hormone-resistant prostate cancer at the Princess Margaret Hospital. Curr Oncol 2010; 17: 24-29.
15. Sekine I, Takada M, Nokihara H et al. Knowledge of efficacy of treatments in lung cancer is not enough, their clinical effectiveness should also be known. J Thorac Oncol 2006; 1: 398-402.
16. Djulbegovic B, Paul A. From efficacy to effectiveness in the face of uncertainty: indication creep and prevention creep. JAMA 2011; 305: 2005-2006.
17. Peppercorn JM, Weeks JC, Cook EF et al. Comparison of outcomes in cancer patients treated within and outside clinical trials: conceptual framework and structured review. Lancet 2004; 363: 263-270.
18. Niraula S, Seruga B, Ocana A et al. The price we pay for progress: a meta-analysis of harms of newly approved anticancer drugs. J Clin Oncol 2012; 30: 3012-3019.
19. Seruga B, Sterling L, Wang L et al. Reporting of serious adverse drug reactions of targeted anticancer agents in pivotal phase III clinical trials. J Clin Oncol 2011; 29: 174-185.